Conclusion and Results (Outcome and follow-up):
Our patient started Denosumab therapy, by which the size of the
acetabular/iliac expansile mass lesion remains stable and the after 7
months of therapy, the follow-up PET/CT shows a significant reduction of
the SUV max from 12 to 6.7. Clinically, the patient reported reduced
pain with good clinical response. Hence, he continued Denosumab for
another six months, anticipating potential surgery. One year after
therapy, the patient only experienced pain upon bending, long walks, and
running. MRI showed stable lesion size with slight internal changes. A
recent PET/CT scan demonstrated a stable lytic lesion with mild
improvement. Currently, the patient resumed his job and reported no pain
or other complaints. He continued Denosumab therapy with regular
follow-ups.